Jubilant Biosys Announces New Facility in India

On Jan. 12, 2026, Jubilant Biosys Limited, a wholly owned subsidiary of Jubilant Pharmova Limited, announced at the JP Morgan Healthcare Conference, which is being held in San Francisco from January 12–15, that it is opening a new discovery and preclinical facility at Noida in India (1). The new facility will double the contract research, development and manufacturing organization’s (CRDMO) chemistry capacity and will combine discovery and early-phase scale up capabilities with R7B labs and two pilot plants. This expansion will meet the company’s demand for fee-for-service contracts.

What will the new facility add?

Comprehensive route scouting, process design and optimization, scalable synthesis development, analytical services will be available, including salt screening and polymorph evaluation and seamless technology transfer to pilot plants all from the specially designed campus. 

The new facility offers a fully unified route from discovery to scale-up and will complement the company’s Chemistry Research Innovation Center (CRIC) in Greater Noida [Delhi], will feature the addition of multiple manufacturing lines, and will increase the number of scientists at the company to 1300. The small-molecule hub is designed to handle quantities from hundreds of grams up to 25kg and combines two pilot plant blocks with co-located discovery labs. A 20,000-sq.-ft. state-of-the-art R&D space will include 15 reactors ranging from 20L through 250L, and the facility may be expanded multifold in the future with room to quadrupole capacity.

“We have grown rapidly over the past year, well above the wider market, by expanding our FFS offerings, which enable innovators to advance discovery projects with lower risk,” Giuliano Perfetti, CEO, Jubilant Biosys Limited, said in a press release (1). “With improving funding conditions, we anticipate even higher demand next year, and this new facility doubles our existing capabilities. From a client perspective, we can now provide faster discovery delivery and integrated scale-up, with projects seamlessly transferred to our GMP facilities ready for any IND filing and commercial phases.”

How are other outsourcing providers meeting capacity needs?

A variety of contract development and manufacturing organizations (CDMOs) made moves in 2025 to expand facilities and services to meet market demands. In August 2025, Bora Pharmaceuticals expanded manufacturing and packaging capabilities at its Maple Grove, Minn facility that will include 100,000 square feet of dedicated shell space to streamline high-volume production (2).

In June 2025, CDMO, Piramal Pharma Solutions, broke ground on a new sterile injectables development and manufacturing facility in Lexington, Ky. The dedicated fill/finish facility will have services for all integrated programs and specialize in sterile compounding, liquid filling, and lyophilization for sterile injectable drug products (3). The expansion, which is expected to be completed by late 2027, will accommodate commercial-scale sterile injectable manufacturing with 24,000 additional square feet, plus a new laboratory, a new filling line, specialized capping machine, external vial washer, and two commercial-size lyophilizers.

SK pharmteco announced a $6.1 million investment at its Rancho Cordova, Calif. facility in October that expands its solid-phase peptide synthesis and purification capabilities (4). The company also is planning a $260 million small-molecule and peptide production facility in South Korea (5).

References

1. Jubilant Biosys Limited. Jubilant Biosys Doubles Early Chemistry Scale-Up Capacity with New Noida Facility in India. Press Release. Jan. 12, 2026.
2. Bora Pharmaceuticals. Bora Pharmaceuticals Announces Multi-Year Expansion for Midwest Manufacturing Site, as Upsher-Smith Entity Split is Finalized. Press Release. Aug. 5, 2025. https://bora-corp.com/bora-pharmaceuticals-announces-multi-year-expansion-for-midwest-manufacturing-site-as-upsher-smith-entity-split-is-finalized/
3. Piramal Pharma Solutions. Piramal Pharma Solutions Breaks Ground on $90M Expansion Plan. Press Release. June 30, 2025.
4. SK pharmteco. SK pharmteco Boosts Domestic Peptide Scale-Up with Investment in California Facility. Press Release. Oct. 23. 2025.
5. SK pharmteco. SK pharmteco Invests $260 Million to Expand Global Small Molecule and Peptide Production. Press Release. Sept. 30, 2024.